Abstract
Viral breakthroughs (VB), defined as having detectable HCV VL while on anti-HCV therapy after achieving maximal suppression, have not yet been characterized with the use of PEG-IFN in HIV/HCV-coinfected patients. We evaluated possible mechanisms for VB among HIV/HCV-coinfected patients receiving PEG-IFN/RBV. Thirty HIV/HCV coinfected patients were treated with PEG-IFN (1.5 mug/kg sc qwk) and RBV (1-1.2 g daily) for 48 weeks. Liver chemistry, HCV VL, genotyping, DNA microarray, and sequencing of HCV E-2 envelope were performed before and during treatment. VB had lower baseline HCV VL but higher ALT and AST than relapsers (ETR) (p < 0.05) and lower CD4+ T lymphocytes (%) than patients with sustained virological responses (SVR), but similar first and second phase HCV viral kinetics (vs. ETR and SVR; p > 0.05). HCV genotypes and envelope sequences were similar for patients with VB pretreatment and at break-through. VB had higher levels of interferon-induced gene (IFIG) expression pretreatment than patients with ETR (p < 0.01). HIV/HCV-coinfected patients have a high rate of VB on PEG-IFN/RBV therapy characterized by higher levels of IFIG expression, immunodeficiency, and hepatic inflammation. Novel strategies are required for the t...Continue Reading
References
Sep 1, 1992·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·S OkadaS Mishiro
Mar 1, 1995·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·L RoffiF Dianzani
Aug 1, 1994·Gastroenterology·F NegroM Ballaré
Sep 1, 1996·British Journal of Haematology·J P HanleyC A Ludlam
Jun 1, 1996·Clinical and Experimental Immunology·G AntonelliF Dianzani
Oct 31, 1998·Journal of Viral Hepatitis·J M Pawlotsky
Jul 27, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·E J HeathcoteD G Albert
Jan 4, 2003·Gastroenterology·Marc G GhanyJay H Hoofnagle
Feb 1, 2003·Annals of Internal Medicine·Mark S Sulkowski, David L Thomas
Apr 18, 2003·AIDS·Mayte Pérez-OlmedaVincent Soriano
Apr 20, 2004·AIDS·Robert P MyersThierry Poynard
Jul 30, 2004·The New England Journal of Medicine·Francesca J TorrianiUNKNOWN APRICOT Study Group
Jul 30, 2004·The New England Journal of Medicine·Raymond T ChungUNKNOWN AIDS Clinical Trials Group A5071 Study Team
Aug 19, 2004·AIDS·Montserrat LagunoJosep Mallolas
Dec 16, 2004·JAMA : the Journal of the American Medical Association·Fabrice CarratUNKNOWN ANRS HCO2 RIBAVIC Study Team
Mar 18, 2006·The Journal of Infectious Diseases·R A LempickiS Kottilil
Aug 8, 2006·Gastroenterology·Hari S ConjeevaramUNKNOWN Virahep-C Study Group